Ozempic Alternatives in 2026: What Actually Works (and What Doesn't)

Ozempic is the most searched weight loss medication in history. It's also consistently out of stock, costs over $1,000/month without insurance, and isn't even approved for weight loss — it's a diabetes drug that happens to cause significant weight reduction.

If you've been told you need Ozempic but can't get it, can't afford it, or just want to understand your options, this guide covers every real alternative: what the evidence says, who each option is right for, and what you'll actually pay.

Why People Want Ozempic in the First Place

Ozempic (semaglutide 0.5mg–2mg) and its weight-loss-approved sibling Wegovy (semaglutide 2.4mg) work by mimicking GLP-1, a hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. The effect: dramatically reduced hunger, smaller portions, and meaningful weight loss — 10-15% of body weight on average, with results that dwarf older medications.

The demand surge created a supply crisis that's never fully resolved. Even when available, brand-name Ozempic or Wegovy costs $935-$1,350/month retail. Most insurance doesn't cover it for weight loss.

So: what are your real options?

Option 1: Compounded Semaglutide (The Best Alternative)

What it is: Pharmacy-compounded semaglutide is the same active molecule as Ozempic/Wegovy, produced by FDA-registered 503B compounding pharmacies. It's identical in mechanism and typically identical in efficacy — the only difference is it's not the brand-name product.

The evidence: Compounded semaglutide using the same molecule (semaglutide base) works the same way because it is the same molecule. The FDA has acknowledged that compounded versions using semaglutide base are not required to use the salt form used in Ozempic. Multiple compounding pharmacies now produce high-quality sterile semaglutide — and patients using it report results consistent with brand-name clinical data.

Who it's right for: Anyone who qualifies for semaglutide (BMI ≥27 with a weight-related condition, or BMI ≥30) but can't access or afford brand-name Ozempic.

Cost: $199-$299/month, including physician oversight. At [Marrow](/semaglutide), compounded semaglutide starts at $249/month with free cold-chain shipping and physician check-ins included.

The catch: Compounded medications aren't FDA-approved (though the pharmacies producing them are registered). The FDA has historically allowed compounding when branded versions are on the shortage list. Regulatory status can change — it's worth discussing with your physician.

Option 2: Compounded Tirzepatide (Often Better)

What it is: Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (weight loss). It's a dual GIP/GLP-1 agonist — it hits two receptors instead of one, which makes it generally more effective than semaglutide alone.

The evidence: The SURMOUNT clinical trials showed tirzepatide producing up to 22.5% body weight reduction at the highest dose — significantly better than semaglutide's 14.9% in the STEP trials. Head-to-head data also shows tirzepatide outperforming semaglutide directly.

Who it's right for: Patients who want maximum efficacy and tolerate dual-agonist side effects. Also a good option if semaglutide hasn't produced adequate results.

Cost: $249-$350/month compounded. [Marrow's tirzepatide program](/tirzepatide) starts at $299/month.

The catch: Same compounding regulatory considerations as semaglutide. Some patients experience more GI side effects with tirzepatide, particularly at higher doses.

Option 3: Phentermine-Topiramate (Qsymia)

What it is: An FDA-approved combination of phentermine (appetite suppressant) and topiramate (anticonvulsant with weight-loss effects). Approved for chronic weight management since 2012.

The evidence: Patients lose an average of 6-11% of body weight — less than GLP-1 medications, but real and meaningful for the right patients. Works best when combined with lifestyle changes.

Who it's right for: Patients who can't tolerate GLP-1 medications or aren't candidates for them. Also useful as an adjunct therapy.

Cost: Generic versions are available, typically $30-$60/month.

The catch: Phentermine is a Schedule IV controlled substance with cardiovascular risks (elevated heart rate, blood pressure). Not appropriate for patients with heart disease or hyperthyroidism. Topiramate carries teratogenicity risk — requires pregnancy prevention in women of childbearing age. Cognitive side effects ("topamax fog") affect some patients.

Option 4: Bupropion-Naltrexone (Contrave)

What it is: A combination of bupropion (antidepressant/smoking cessation medication) and naltrexone (opioid antagonist). Targets dopamine and opioid reward pathways to reduce food cravings.

The evidence: Average weight loss of 5-9% in clinical trials — modest compared to GLP-1 medications. Where it shines is in patients with emotional eating or food-reward dysregulation, where the mechanisms are particularly relevant.

Who it's right for: Patients with binge eating tendencies, emotional eating, or those who haven't responded to other approaches.

Cost: Generic bupropion is cheap; naltrexone is available generically as well. Combined formulation is more expensive, but components can sometimes be prescribed separately.

The catch: Bupropion has a black box warning for suicidality in patients under 24. Contraindicated with seizure disorders, eating disorders like bulimia, MAOIs. The naltrexone component means opioid pain medications won't work if needed.

Option 5: Metformin

What it is: First-line diabetes medication with modest weight loss effects. Not a weight loss drug, but commonly prescribed off-label.

The evidence: Metformin produces 2-3% body weight loss on average — much less than GLP-1 options. Its main mechanism is reducing hepatic glucose production, which doesn't directly target the hunger/satiety pathways that GLP-1 medications target.

Who it's right for: Patients with prediabetes or insulin resistance who need glycemic control along with modest weight management. Not a substitute for GLP-1 medications in patients with significant weight loss goals.

Cost: Very cheap — often $4-$10/month generic.

The catch: GI side effects (nausea, diarrhea) are common, especially when starting. Requires monitoring of B12 levels with long-term use.

Option 6: Liraglutide (Saxenda/Victoza)

What it is: An older GLP-1 agonist — the predecessor to semaglutide. Saxenda is the weight-loss-approved version; Victoza is the diabetes version of the same molecule.

The evidence: Average weight loss of 5-8% in clinical trials — less effective than semaglutide or tirzepatide, and requires daily injections (semaglutide and tirzepatide are weekly).

Who it's right for: Mostly of historical interest at this point. Some patients who can't tolerate weekly GLP-1 medications prefer the daily titration, but most guidelines now favor semaglutide or tirzepatide as first-line GLP-1 options.

Cost: Brand-name Saxenda is expensive ($1,300+/month). Some compounding pharmacies offer liraglutide, though it's less common than semaglutide or tirzepatide.

The catch: Daily injections are inconvenient. Less effective than newer options. Not typically the right first choice in 2026.

Option 7: Lifestyle Interventions (The Non-Medication Option)

This is worth including honestly: structured lifestyle programs work. The Diabetes Prevention Program showed 58% reduction in diabetes risk with 7% body weight loss through diet and exercise — better than metformin alone.

The evidence: High-protein diets (targeting 1g protein per pound of goal body weight), consistent resistance training, improved sleep, and stress management produce real results. Not 15% body weight loss for most people, but real, sustainable change.

Who it's right for: Everyone. Ideally as a complement to medication, not a replacement — but for patients who aren't medication candidates or don't want medication, rigorous lifestyle intervention is genuinely effective.

Cost: Minimal (gym membership, whole food grocery costs, a coach if desired).

The catch: Requires significant behavioral change and consistency. Most people struggle to sustain without pharmacological support for appetite regulation. That's not a character flaw — it's physiology.

How to Choose

The decision tree for most patients:

1. BMI ≥30, or BMI ≥27 with weight-related condition? → GLP-1 first. Start with compounded semaglutide or tirzepatide for cost and access.
2. Already tried semaglutide, want stronger results? → Upgrade to tirzepatide (better clinical efficacy in trials).
3. Can't tolerate GLP-1 side effects? → Consider phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave).
4. Prediabetes primary concern, modest weight loss goal? → Metformin is reasonable, often combined with lifestyle.
5. No medication wanted? → Structured lifestyle program with high-protein diet + resistance training.

For most people reading this in 2026, compounded semaglutide or tirzepatide is the best option — same active molecules as Ozempic/Mounjaro, dramatically lower cost, and efficacy data that's difficult to argue with.

The Bottom Line on Ozempic Alternatives

Ozempic isn't special. The molecule is — but Ozempic as a brand is just one delivery vehicle for semaglutide. Compounded semaglutide from a reputable pharmacy delivers the same results at a fraction of the price.

If cost or access is your barrier, compounded GLP-1 therapy is the most evidence-backed path forward. If GLP-1 medications aren't right for you medically, Qsymia and Contrave are legitimate alternatives with meaningful evidence. And if you're not ready for medication, a rigorous lifestyle program is more effective than most people realize.

At Marrow, we help you figure out which path is right for your physiology and goals — not just hand you a prescription. [Start your intake](/start) and talk to a physician who actually takes time to understand your situation.